R&D channel feed – Endpoints News

R&D channel feed

Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops

9 years ago

Corbus brags about another PhII success for its lead drug, but shares slide early

9 years ago

Hit with a trial failure, Agenus brings out the ax to chop staff, reorganize

9 years ago

Novartis gets a speedy review for its CAR-T pioneer as FDA lines up a marketing decision

9 years ago

With a new primary endpoint and the disappearance of a trial site, tiny Ritter claims a big clinical victory

9 years ago

Why wait? Trump mounts an early raid on NIH’s ’17 budget in search of some spending money

9 years ago

Vertex shares surge as its cystic fibrosis combo proves marginally positive, but payers may not be so impressed

9 years ago

Vertex is reorganizing and consolidating R&D, shuttering a site in Canada

9 years ago

Bristol-Myers partners with Parker Institute, CRI on a next-gen twist on translational R&D

9 years ago

Pumped by an early glimpse of efficacy, Newron charts a pivotal course for schizophrenia drug

9 years ago

A Foamix acne drug PhIII bombs, sending shares into a tailspin

9 years ago

Allergan scores a PhIII win with an acne drug now headed to the FDA

9 years ago

Eli Lilly unveils an $850M makeover as Trump pounds the table for new US jobs, manufacturing

9 years ago

Xenon’s lead in-house drug flops in a mid-stage test and stock plunges lower

9 years ago

Sleuthy Google upstart Calico forges a rare biotech collaboration on aging with Novartis-backed C4

9 years ago

Ultragenyx shares tumble lower after rare disease drug fails PhII trial

9 years ago

Teva denies big layoffs are planned, but will push greater efficiency and shutter floundering efforts

9 years ago

Staggered by a Duchenne patient’s death, Akashi finally gets a green light to get back into the clinic

9 years ago

Once scored as a potential blockbuster, Novartis’ serelaxin fizzles in critical cardio outcomes test

9 years ago

Novartis boasts a big new advantage for Cosentyx as data indicate the blockbuster can modify psoriasis

9 years ago

Struggling Heat gets a warm response to a snapshot on cancer vax data

9 years ago

SutroVax raises $64M with plans to challenge Pfizer’s megablockbuster Prevnar 13 for the heavyweight title in vaccines

9 years ago

Aevi shares smashed by a trial failure for ADHD genetic subgroup

9 years ago

Laggard Lilly says its CDK 4/6 drug abemaciclib scored in PhIII, while rivals at Novartis, Pfizer sharpen their knives

9 years ago

First page Previous page 303 304 305306307 308 309 Next page Last page